A Simple Stratification Factor Prognostic for Survival in Advanced Cancer: The Good/Bad/Uncertain Index

Sloan, Jeff A.; Loprinzi, Charles L.; Laurine, John A.; Novotny, Paul J.; Vargas-Chanes, Delfino; Krook, James E.; O’Connell, Michael J.; Kugler, John W.; Tirona, Maria Tria; Kardinal, Carl G.; Wiesenfeld, Martin; Tschetter, Loren K.; Hatfield, Alan K.; Schaefer, Paul

doi:10.1200/jco.2001.19.15.3539

Cited by 63 publications

(39 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are consistent with findings from other studies. 9,32,34,35 Second, we found that the LASA items correlated strongly with similar scales on other, wellvalidated, multi-item scales that are frequently used in cancer patients, thereby supporting the concurrent validity and construct validity of the LASA. Specifically, the Overall QOL LASA item correlates strongly with the overall score on the FACT-Br, the Overall SDS score, and the Overall POMS score.…”

Section: Discussionmentioning

confidence: 67%

Validation of Single-Item Linear Analog Scale Assessment of Quality of Life in Neuro-Oncology Patients

Locke

Decker

Sloan

et al. 2007

Journal of Pain and Symptom Management

Self Cite

208

132

View full text Add to dashboard Cite

Patient quality-of-life (QOL) assessment requires balancing the detail provided by multi-item assessments with the reduced burden of single-item assessments. In this project, we investigated the psychometric properties of single-item linear analog scale assessments (LASAs) for patients with newly diagnosed high-grade gliomas. Measures included QOL LASAs (overall, physical, emotional, spiritual, intellectual), Symptom Distress Scale (SDS), Profile of Mood States (POMS; overall, confusion, fatigue), and Functional Assessment for Cancer Therapy-Brain (FACT-Br; overall, brain, physical, emotional). Associations of LASA measures with SDS, POMS, and FACT-Br domains and with Eastern Cooperative Oncology Group performance score (PS) and Mini-Mental State Examination (MMSE) were assessed. Repeated measures ANOVA models compared the change over time of LASAs and SDS, POMS, and FACT-Br. Two hundred five patients completed the assessments across three time points. To allow comparison across measures, all scores were converted to a scale of 0-100 with higher scores indicating better QOL. LASA mean scores ranged from 60-78; SDS, POMS, and FACT-Br ranged from 62-81. FACT-Br physical (P<0.001) and POMS fatigue subscale (P=0.005) decreased over time, as did LASA physical (P=0.08). LASA scales were strongly associated with corresponding scales on SDS, POMS, and P<0.001). LASA was negatively associated with PS and positively with MMSE, with associations similar in magnitude to the other QOL and psychosocial measures. The data suggest that the singleitem LASA scales are valid for assessing QOL of cancer patients and are an appropriate alternative when a shorter instrument is warranted.

show abstract

Section: Discussionmentioning

confidence: 67%

Validation of Single-Item Linear Analog Scale Assessment of Quality of Life in Neuro-Oncology Patients

Locke

Decker

Sloan

et al. 2007

Journal of Pain and Symptom Management

Self Cite

208

132

View full text Add to dashboard Cite

show abstract

“…For example, significant differences in the assessment of performance status have been reported between oncologists, nurses and patients, oncologists being the most optimistic in their assessment and patients the least (Ando et al, 2001). As a result there is continuing interest in the development of prognostic scores, which better reflect clinical outcome (Bennett and Ryall, 2000;Sloan et al, 2001).…”

Section: Discussionmentioning

confidence: 99%

Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer

et al. 2004

View full text Add to dashboard Cite

The value of an inflammation-based prognostic score (GPS) was compared with performance status (ECOG) in patients (n ¼ 109) receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. On multivariate analysis with ECOG, white cell count and the GPS entered as covariates, only the GPS was a significant independent predictor of survival (HR 1.88, 95% CI 1.25 -2.84, P ¼ 0.002). Non-small-cell lung cancer (NSCLC) is the most common cause of cancer death in North America and Western Europe. Most patients present with advanced inoperable disease; the prognosis of these patients is extremely poor. In selected patients, platinum-based regimens have been shown to have a beneficial but modest impact on survival (Klastersky and Paesmans, 2001). Conventionally, the selection of patients for chemotherapy has been based on clinicopathological criteria, including age, stage and performance status (Numico et al, 2001).There is increasing evidence that the presence of a systemic inflammatory response, as evidenced by elevated circulating concentrations of C-reactive protein concentrations, is associated with early recurrence and poor survival, independent of stage, in a variety of common solid tumours (Ikeda et al, 2003;McMillan et al, 2003). In advanced disease, an elevated C-reactive protein has also been shown to associated with poor survival (O'Gorman et al, 2000;Mahmoud and Rivera, 2002).Furthermore, in an unselected cohort of patients with inoperable NSCLC, the Glasgow Prognostic Score (GPS), a cumulative prognostic score based on C-reactive protein and albumin, had similar prognostic value to that of stage and performance status (Forrest et al, 2003). The question of whether the GPS would be useful in the selection of appropriate treatment for patients with inoperable NSCLC remains to be determined.The aim of the present study was to assess the value of the GPS in patients receiving chemotherapy for inoperable NSCLC. MATERIALS AND METHODS Study designPatients presenting with inoperable NSCLC (stages III and IV) to a single multidisciplinary oncology clinic in Glasgow Royal Infirmary between March 2000 and June 2003 were studied prospectively. All patients had cytologically or histologically confirmed disease and were staged on the basis of clinical findings, chest X-ray and, where appropriate, bronchoscopy, liver ultrasound, isotope bone scan and computerised tomography of the thorax, according to the American Thoracic Society TNM classification (Mountain, 1991).Clinical stage, tumour type and performance status (Eastern Cooperative Oncology Group, ECOG) were recorded at the time of diagnosis. A blood sample was also obtained for the measurement of white cell count, albumin and C-reactive protein concentrations. Patients received between one and six cycles of platinum-based chemotherapy.The study was approved by the Research Ethics Committee of Glasgow Royal Infirmary. MethodsBlood parameters: Routine laboratory measurements of albumin and C-reactive protein concentration were carried out. The coeffic...

show abstract

“…For example, significant differences in the assessment of performance status have been reported between oncologists, nurses and patients, oncologists being the most optimistic in their assessment and patients the least (Ando et al, 2001). There is therefore a continuing interest in prognostic factors, which better reflect response to treatment and survival (Bennett and Ryall, 2000;Sloan et al, 2001).…”

Section: Discussionmentioning

confidence: 99%

The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer

et al. 2004

View full text Add to dashboard Cite

The prognostic value of C-reactive protein, compared with ECOG performance status (ECOG-ps), in patients receiving alphainterferon treatment for advanced renal cancer was assessed in 58 patients. In all, 55 patients died on follow-up. On multivariate analysis with ECOG-ps and C-reactive protein entered as covariates, only C-reactive protein was a significant independent predictor of survival (HR 2.03, 95% CI 1.09 -3.80, P ¼ 0.026).

show abstract

A Simple Stratification Factor Prognostic for Survival in Advanced Cancer: The Good/Bad/Uncertain Index

Cited by 63 publications

References 22 publications

Validation of Single-Item Linear Analog Scale Assessment of Quality of Life in Neuro-Oncology Patients

Validation of Single-Item Linear Analog Scale Assessment of Quality of Life in Neuro-Oncology Patients

Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer

The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer

Contact Info

Product

Resources

About